Opendata, web and dolomites

BiopSense SIGNED

Proof of concept and pre-commercialisation of personalised liquid biopsies in cancer therapy

Total Cost €


EC-Contrib. €






 BiopSense project word cloud

Explore the words cloud of the BiopSense project. It provides you a very rough idea of what is the project "BiopSense" about.

operation    cheaper    follow    extremely    service    40    boosting    transferring    competing    biopsies    medication    complete    erc    consultation    shield    continue    oncology    university    allowed    group    ultraseek    verified    options    commercialization    trl    biomarkers    spectrometric    started    period    presented    kit    diagnostics    panel    hospitals    closest    steering    determined    blood    health    chip    accuracy    preparation    panels    single    biotech    international    polymorphism    screening    medical    platform    sensitive    personalised    price    care    centers    spin    post    ipr    chemistry    upgrading    diagnostic    partnering    conferences    business    components    licensing    market    automated    agena    invention    customized    prep    innovation    cog    nucleotide    lab    device    liquid    patent    mass    licensors    local    investors    detection    negotiations    competitor    extended    consist    flexible    treatment    point    personalized    convention    clarified    combined    companies    investor    designing    either    cancer    sensitivity   

Project "BiopSense" data sheet

The following table provides information about the project.


Organization address
postcode: 40100

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 149˙999 €
 EC max contribution 149˙999 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    JYVASKYLAN YLIOPISTO FI (JYVASKYLA) coordinator 149˙999.00


 Project objective

Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOPSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOPSENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


Pathogenesis and treatment of splicing factor mutant myelodysplastic syndromes

Read More  

IL7RsignaTHER (2020)

Antibody-based IL-7R targeted therapies

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More